Treatment type
Gazyva (obinutuzumab) — infusion to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
The United States approved Gazyva (obinutuzumab) on 25 September 2026 to reduce relapses of childhood-onset nephrotic syndrome.
This is for families and adults living with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete…
Isembyld (apitegromab-mstn) — a once-every-4-weeks IV medicine that targets muscle for people with SMA already on an SMN2 treatment
FDA approval on 11 September 2026 for Isembyld (apitegromab-mstn) injection — a muscle-targeted intravenous medicine — for spinal muscular atrophy (SMA) in…
This is for children and adults living with SMA who are already on an SMN2-targeted treatment (such as nusinersen or risdiplam) and who may be candidates for…
Revtorpyk (gedatolisib) — IV pan-PI3K/mTOR inhibitor for HR+/HER2−, PIK3CA-wild-type advanced breast cancer
On 14 July 2026 the FDA labelled Revtorpyk (gedatolisib) for injection — an intravenous kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and…
Revtorpyk is a US-labelled IV pan-PI3K / mTOR inhibitor used with fulvestrant, with or without palbociclib, for adults whose HR+/HER2− advanced breast cancer…
Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP)
The FDA labelled an intravenous activin A–blocking monoclonal antibody on 19 August 2026 to reduce formation of new heterotopic ossification (HO) lesions and…
Pasatru (garetosmab) is an infusion every 4 weeks for adults with fibrodysplasia ossificans progressiva.
Lumvoa (veligrotug-vvze) for thyroid eye disease (active and chronic)
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease activity or duration on 26 June 2026. The labelled…
Lumvoa (veligrotug) is an infusion for thyroid eye disease, whether the disease is active or long-standing.